Gapping up
In reaction to strong earnings/guidance:
- III +19%, HZNP +16.1%, KOS +5%, CRNT +4.9%, SPNS +4.8%, GOGO +4.3%, FDC +4%, ON +3%, TSN +2.5%, RTTR +1.7%, FOLD +1.2%, CNNX +0.5%
M&A news:
- NXTM +39.1% (to be acquired by Fresenius Medical Care (FMS) for $30.00 per share)
- COL +6.7% (reports of potential UTX deal)
Other news:
- MYOK +33.5% (announces 'positive' topline data from the first patient cohort of its Phase 2 PIONEER-HCM study; also reported earnings)
- EROS +22% (report that the company is in talks with Apple (AAPL) and other parties to sell its entire content library of films and music)
- CLNT +14.3% (to purchase ECoin Redemption Codesg; signs an agreement w/ ECoin Global for the purchase of ECoin redemption codes with an aggregate value of $50 million for total consideration of $20 million)
- KDMN +13.6% (granted orphan drug designation by the FDA for tesevatinib for the treatment of non-small cell lung cancer with epithelial growth factor receptor-activating mutations)
- CYCC +8.3% (selects a recommended Phase 2 dose from part 1 of a dose-escalating, Phase 1, first-in-human, clinical study of CYC065)
- SODA +1.1% (continued strength)
- MASI +0.9% (provides study results for SpHb in trauma patients with low hemoglobin levels)
Analyst comments:
- LLL +2% (added to Conviction Buy List at Goldman)
- GRUB +1.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- DE +1.5% (added to Conviction Buy List at Goldman)
- CLH +1.2% (upgraded to Equal Weight from Underweight at Barclays )
- NICE +1.1% (target raised to $84 from $76 at Chardan Capital Markets)